RGC
Regencell Bioscience Holdings Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$5.79
−2.85%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.01
From 52W high−89.05%
Volume93975.00
Market cap$2.87B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.01
From 52W high
−89.05%
Volume
93975.00
Market cap
$2.87B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−407.8x
P/E (TTM)
—
RSI (14)
48.3
MomentumView details →
1D Return
−2.85%
YTD Return
−72.14%
SummaryUpdated Dec 1, 2025
Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a Traditional Chinese Medicine (TCM) bioscience company founded in 2014 and headquartered in Causeway Bay, Hong Kong. The company went public on July 16, 2021, and focuses on developing innovative treatments for neurocognitive disorders using traditional Chinese medicine principles combined with modern scientific research methods. Regencell is currently in the research and development phase, with no commercial products yet generating revenue.
Similar companies
Latest newsMore news →
No recent news for RGC.